questions for agm, page-46

Well, most of the questions I raised intitially are more or less answered satisfactorily

The company certainly is maintaining its strategy and there are positive reassurances that there is space in the market ('There is unlikely to be just one "winner" in the HCV race' and 'Direct Acting Antivirals - Race isn't over'). These are reassuring pronouncements.

Note that it is stated that most likely there will be a number of treatments with different combinations of drugs in which there is a good possibility that p7 inhibitors (only BIT225 in this class so far) will be included in at least some treatments.

Initial HIV trial results expected in Q1/2013. Also more progress on the BIT314 anticipated moving to manufacture and safety studies in 1H2013.

No mention of partnering, but I guess the assumption is that may more likely once results of further trials are in.

Financial position is good.

All in all, I think a good report which justifies the faith of holders in the company. Switching my view back to buy.